Canaccord analyst Edward Nash lowered the firm’s price target on Rani Therapeutics to $9 from $21 and keeps a s.Buy rating on the shares. The firm updated its model to reflect the company’s latest financial results with the decrease associated with an updated estimate of the company’s clinical development timeline, based on historical approvals.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RANI:
- Rani Therapeutics price target lowered to $12 from $16 at H.C. Wainwright
- Rani Therapeutics reports Q4 EPS (27c), consensus (31c)
- Rani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate Update
- RANI Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results
